艾伯维公司(ABBV)今日盘中大涨8.21%,引发了市场的广泛关注。
消息面上,艾伯维预计其新型免疫学药物Skyrizi和Rinvoq的合并销售额到2027年将超过310亿美元,远高于此前的预期。这主要是因为两款新药在临床上表现出色,销售前景非常可观,有望成为公司未来的重要增长动力。
另一方面,虽然艾伯维的过去明星产品Humira的销售受到生物仿制药冲击而大幅下滑,但公司通过新药研发进行产品升级切换,有望扭转颓势。而根据公司数据,2025年每股收益预计将达到12.12至12.32美元的水平,超出市场预期,进一步增强了投资者对公司长期增长的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.